Study finds that Gardasil is ‘More Cost Effective’ than Cervarix

According to new data published in the British Medical Journal, the cervical cancer vaccine, Gardasil, produced by Merck and Sanofi, may be more cost effective than its competitor GlaxoSmithKline’s Cervarix. However, the differential benefits of both vaccines remain unclear, say researchers from the Health Protection Agency. The study has been updated from the one previously

Continue Reading